-
公开(公告)号：US11795152B2
公开(公告)日：2023-10-24
申请号：US17392008
申请日：2021-08-02
发明人： Minhua Chen , Jing Zhang , Siming Zou
IPC分类号： C07D263/57
CPC分类号： C07D263/57 , C07B2200/13
摘要： The present disclosure relates to novel crystalline forms of tafamidis (hereinafter referred to as compound I) and processes for preparation thereof. The present disclosure also relates to pharmaceutical composition containing the novel crystalline forms, use of the novel crystalline forms for preparing drugs treating disease caused by transthyretin-mediated amyloidosis. The crystalline forms of tafamidis of the present disclosure have one or more improved properties compared with crystalline forms of prior art and have significant value for future drug optimization and development.
-
公开(公告)号：US20210332014A1
公开(公告)日：2021-10-28
申请号：US17278138
申请日：2019-09-20
发明人： Minhua Chen , Yanfeng Zhang , Xiaoting Zhai , Jing Zhang , Qun Zhang
IPC分类号： C07D215/233
摘要： The present invention relates to novel cabozantinib malate crystalline forms, preparation methods for the cabozantinib malate, a pharmaceutical composition comprising the novel cabozantinib malate crystalline forms, and use of the novel cabozantinib malate crystalline forms in the preparation of MET, VEGFR1/2/3, ROS1, RET, AXL, NTRK, and KIT inhibitors and pharmaceutical preparations for treating cancers such as thyroid cancer, lung cancer, kidney cancer and liver cancer. The cabozantinib malate crystalline forms provided by the present invention has one or more improved properties compared with the prior art, and the preparation method for the cabozantinib malate provided by the present disclosure has a lower cost and better quality of the obtained product compared with the prior art, having important value for future optimization and development of this drug.
-
3.发明申请公开(公告)号：US20210147471A1
公开(公告)日：2021-05-20
申请号：US16620115
申请日：2018-05-21
发明人： Minhua Chen , Yanfeng Zhang , Chunxiang Huang , Xiaoyu Zhang
IPC分类号： C07J41/00
摘要： The present disclosure relates to novel crystalline forms of compound (I) and processes for preparation and use thereof. Crystalline forms CS3, CS2, CS5 and CS8 of compound (I) of the present disclosure have advantages in at least one aspect of solubility, stability, melting point, hygroscopicity, particle size, bioavailability, processability, purification effect, flowability, adhesiveness, stability in drug product, in vitro and in vivo dissolution, etc., which provides new and better choices for preparation of drug product containing compound (I) and has significant values for future drug development.
-
公开(公告)号：US20200339524A1
公开(公告)日：2020-10-29
申请号：US16643011
申请日：2018-08-23
发明人： Minhua Chen , Yanfeng Zhang , Xiaoting Zhai , Kaiqiang Yan , Chaohui Yang
IPC分类号： C07D271/06
摘要： The present disclosure is related to crystalline forms of ozanimod hydrochloride, as well as preparation method thereof. The crystalline form of ozanimod hydrochloride provided by the present disclosure can be used for treating autoimmune diseases, particularly multiple sclerosis and ulcerative colitis. The crystalline form of the present disclosure has advantages in at least one aspect of solubility, melting point, stability, dissolution, bioavailability and processability and provides a new and better choice for the preparation of drug product containing ozanimod, and has significant value for drug development.
-
5.发明授权公开(公告)号：US10759779B2
公开(公告)日：2020-09-01
申请号：US16777121
申请日：2020-01-30
发明人： Minhua Chen , Yanfeng Zhang , Chunxiang Huang , Xiaoyu Zhang
IPC分类号： C07D401/12
摘要： The present disclosure provides a novel crystalline form of Lemborexant and processes for preparation thereof. Pharmaceutical composition containing Lemborexant, and use of Lemborexant for preparing orexin receptor antagonist drug, and use of Lemborexant for preparing drugs treating insomnia and irregular sleep-wake rhythm disorder are also provided. The crystalline form of the present disclosure have one or more improved properties compared with crystalline forms of prior arts, and has significant values for future drug optimization and development.
-
6.发明授权公开(公告)号：US11339158B2
公开(公告)日：2022-05-24
申请号：US16771799
申请日：2018-12-26
发明人： Minhua Chen , Yanfeng Zhang , Chaohui Yang , Chunxiang Huang
IPC分类号： C07D471/04
摘要： A crystalline form of valbenazine ditosylate, processes for preparation thereof, a pharmaceutical composition containing the crystalline form, use of the crystalline form for preparing vesicular monoamine transporter 2 inhibitor drugs, and use of the crystalline form for preparing drugs treating tardive dyskinesia.
-
公开(公告)号：US11091494B2
公开(公告)日：2021-08-17
申请号：US16959700
申请日：2018-11-20
发明人： Minhua Chen , Yanfeng Zhang , Yuan Liu , Jianming Wang
IPC分类号： C07D487/04
摘要： The present disclosure relates to novel crystalline forms of acalabrutinib and processes for preparation thereof. The present disclosure also relates to pharmaceutical compositions containing acalabrutinib, use of acalabrutinib for preparing Bruton's tyrosine kinase inhibitor drug, and use of acalabrutinib for preparing drugs treating mantle cell lymphoma. The crystalline forms of the present disclosure have one or more improved properties compared with prior art, and have significant value for future drug optimization and development.
-
公开(公告)号：US11066384B2
公开(公告)日：2021-07-20
申请号：US17033922
申请日：2020-09-28
发明人： Minhua Chen , Yanfeng Zhang , Xiaoting Zhai , Jiale Qian , Yuhao Chen , Chaohui Yang
IPC分类号： C07D401/04
摘要： The present disclosure relates to novel crystalline forms of ARN-509 (structure shown in formula I), processes for preparation of the novel crystalline forms, pharmaceutical composition of the novel crystalline forms, and uses of the novel crystalline forms for preparing drug products of androgen receptor antagonists and for treating prostate cancer. The crystalline forms of ARN-509 provided by the present disclosure have one or more improved properties compared with the prior art, and is of great value to the future optimization and development of drugs.
-
公开(公告)号：US20210087195A1
公开(公告)日：2021-03-25
申请号：US17050329
申请日：2019-03-05
发明人： Minhua Chen , Yanfeng Zhang , Yuan Liu , Long Zhang , Chaohui Yang
IPC分类号： C07D487/04
摘要： The present disclosure relates to novel crystalline forms of acalabrutinib and processes for preparation thereof. The present disclosure also relates to pharmaceutical compositions containing acalabrutinib, use of acalabrutinib for preparing Bruton's tyrosine kinase inhibitor drugs, and use of acalabrutinib for preparing drugs treating mantle cell lymphoma. The crystalline forms of the present disclosure have one or more improved properties compared with prior art, and have significant value for future drug optimization and development.
-
10.发明申请公开(公告)号：US20210078993A1
公开(公告)日：2021-03-18
申请号：US16771799
申请日：2018-12-26
发明人： Minhua Chen , Yanfeng Zhang , Chaohui Yang , Chunxiang Huang
IPC分类号： C07D471/04
摘要： A crystalline form of valbenazine ditosylate, processes for preparation thereof, a pharmaceutical composition containing the crystalline form, use of the crystalline form for preparing vesicular monoamine transporter 2 inhibitor drugs, and use of the crystalline form for preparing drugs treating tardive dyskinesia.
-
-
-
-
-
-
-
-
-
搜索结果
39 条记录 (耗时 0.021 秒)
